HK Stock Market Move | PA GOODDOCTOR (01833) rises over 8%; net profit up 35% year-on-year in the first three quarters; AI capabilities extend to diverse scenarios and populations.
PA GOODDOCTOR (01833) rose over 8%, up 6.37% as of press time, at HK$5.925, with a turnover of HK$51.0786 million.
PA GOODDOCTOR (01833) rose over 8%, up 6.37% as of press time at HK$5.925, with a turnover of HK$51.0786 million.
On the news front, PA GOODDOCTOR recently released its results report for the first three quarters of 2026. During the period, the company recorded total revenue of RMB3.508 billion and net profit of RMB248 million, up 35% year-on-year. During the period, the company continued to deepen AI capability building and application implementation, building differentiated advantages through a "human + machine + ecosystem" closed loop, and driving steady improvements in the quality and efficiency of professional medical services. During the period, the number of users of the company's AI doctor continued to grow to nearly 13 million.
In serious medical scenarios, the company further upgraded its AI multidisciplinary consultation (MDT) assistance platform for complex diseases. As of the end of the reporting period, it had covered four major categories of diseases, with the accuracy of multidisciplinary consultation treatment plans for complex diseases at approximately 90%. The continued expansion of disease coverage reflects the gradual deepening of AI capability application in the diagnosis and treatment of complex diseases. In proactive health management scenarios, the company launched during the period the digital intelligent health management service "Ping An Zhixiang Private Coach" under the "AI + real person" model, building a full-process exercise and health management closed loop around "assessment-training-consolidation," and creating a dual-instructor companion training mechanism featuring exclusive fitness private coaches and AI intelligent coaches. At the same time, the application boundaries of AI capabilities continued to extend to diverse populations and cross-border scenarios.
Related Articles

HK Stock Market Move | Pharmaceutical stocks continue to strengthen, with Sino Biopharmaceutical leading gains after securing a US$7 billion BD deal; outbound BD in the first three quarters nears full-year total of last year.

HK Stock Market Move | KINGDEE INT'L (00268) rose nearly 15% in morning trading; core capabilities of AI products upgraded; Lingji paid customers have exceeded 3,700

Arm (ARM.US) Q2 Earnings Call: Confidence in AGI CPU Commercialization "Strongest to Date"; Data Center Royalties to Maintain Triple-Digit Growth for Years to Come
HK Stock Market Move | Pharmaceutical stocks continue to strengthen, with Sino Biopharmaceutical leading gains after securing a US$7 billion BD deal; outbound BD in the first three quarters nears full-year total of last year.

HK Stock Market Move | KINGDEE INT'L (00268) rose nearly 15% in morning trading; core capabilities of AI products upgraded; Lingji paid customers have exceeded 3,700

Arm (ARM.US) Q2 Earnings Call: Confidence in AGI CPU Commercialization "Strongest to Date"; Data Center Royalties to Maintain Triple-Digit Growth for Years to Come






